Sharma indicated the company expects to "complete enrollment with 62 to 65 patients across a wide range of solid tumors by the June 2025" for the LP-184 Phase 1a trial, with comprehensive data ...
The QPF5001 X-band FEM incorporates a power amplifier, low-noise amplifier (LNA), and limiter. Half the size of a discrete component implementation, the MCM targets the 8- to 12-GHz X-Band. The ...
CEO Panna Sharma stated that "the first quarter of 2025 represents a pivotal inflection point for Lantern Pharma." He highlighted significant progress in the clinical portfolio and the expansion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback